## Special Issue

## Novel Biomarkers in Alzheimer's Disease

## Message from the Guest Editor

Alzheimer's disease (AD) is the most common form of dementia in the elderly, affecting about 46\(\summillion\) people worldwide. It is clinically characterized by the progressive deterioration of memory and other cognitive functions that results in the loss of autonomy and which ultimately requires full-time medical care. The diagnosis of AD currently relies on clinical criteria, including mental status assessment, neurological examination, and brain imaging tests. However, these imaging methods are conclusive only in the advanced stages of disease, whereas AD physiopathology begins several decades before onset of the first symptoms. It is therefore particularly important to identify potential biomarkers that can be used in the early detection of AD, i.e., before clinical signs appear, as well as to evaluate the efficiency of therapeutic agents under testing and to thus accelerate the therapeutic discovery process. In this Special Issue, the current knowledge as well as future perspectives on the role of biomarkers in screening, diagnosis, treatment and follow-up of Alzheimer's disease will be discussed.

### **Guest Editor**

Dr. Chiara Villa

Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

## Deadline for manuscript submissions

closed (5 July 2020)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/33684

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

#### Editor-in-Chief

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

